Endothelial dysfunction and coronary risk reduction

Journal of Cardiopulmonary Rehabilitation

Volumn 18, Issue 1, 1998, Pages 60-67

  Charo, Satish ^a   Gokce, Noyan ^a   Vita, Joseph A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; EXERCISE; FAT INTAKE; HUMAN; SHEAR STRESS; VASCULAR ENDOTHELIUM;

ACUTE DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CHRONIC DISEASE; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; ESTROGEN REPLACEMENT THERAPY; EXERCISE; HUMANS; NITRIC OXIDE; RISK FACTORS;

EID: 0031941528     PISSN: 08839212     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008483-199801000-00008     Document Type: Article

References (93)

1. American Heart Association: Heart and Stroke Facts: 1996 Statistical Supplement.
2. Kannel WB: Clinical misconceptions dispelled by epidemiological research. Circulation 1995;92:3350-3360.
3. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald EB: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
6. Levine GN, Keaney JF Jr, Vita JA: Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521.
7. Enos WF, Holmes RH, Byer J: Coronary disease among United States soldiers killed in action in Korea: Preliminary report. JAMA 1953;152:1090-1093.
8. Moncada S, Higgs A: The L-arginine nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
9. Olesen SP, Clapham DE, Davies PF: Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature 1988;331:168-170.
10. Ignarro LJ: Endothelium-derived nitric oxide: Actions and properties. FASEB 1989;3:31-36.
11. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051.
12. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO: Nitric oxide activity in the human coronary circulation. Impact of risk factors for atherosclerosis. J Clin Invest 1995;95:1747-1755.
13. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, Creager MA: Flow-induced vasodilation of the human brachial artery is impaired in patients ( years of age with coronary artery disease. Am J Cardiol 1996;78:1210-1214.
14. Radomski MW, Palmer RMJ, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to the vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
15. Kubes P, Suzuki M, Granger DN: Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-4655.
16. Moncada S, Vane JR: Pharmacology and endogenous roles or prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978;30:293-331.
17. Cohen RA, Vanhoutte PM: Endothelium-dependent hyperpolarization: Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-3349.
18. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
19. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(suppl 6 pt 2):14-13.
20. Tesfamariam B, Brown ML, Deykin D, Cohen RA: Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990;85: 929-932.
21. Hekman CM, Loskutoff DJ: Fibrinolytic pathways and the endothelium. Semin Thromb Hemost 1987;13:514-527.
22. Loskutoff D, Edgington T: Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977;74:3903-3907.
23. Esmon NL, Owen WG, Esmon CT: Isolation of a membrane bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982;257:859-864.
24. Marcum JA, Rosenberg RD: Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985;126:365-372.
25. Marcus AJ, Broekman MJ, Drosopoulos JHF, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR: The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997;99:1351-1360.
26. Weis JR, Pitas RE, Wilson BD, Rodgers GM: Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB 1991;5:2459-2469.
27. Collins T: Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest 1993;68:499-508.
28. Horvath CJ, Ferro TH, Jesmok G, Malik AB: Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci USA 1988;85:9219-9223.
29. Libby P: Molecular basis of the acute coronary syndromes. Circulation 1995;91:2844-2850.
30. Clowes AW, Reidy MA, Clowes MM: Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333.
31. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
32. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky MJ: Cultured endothelial cells produce a heparin like inhibitor of smooth muscle cell growth. J Cell Biol 1981;90:372-379.
33. Schwartz SM, Gajdusek CM, Seiden SC: Vascular wall growth control: The role of endothelium. Atherosclerosis 1981;1:107-126.
34. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497.
35. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-234.
36. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994;93:50-55.
37. Keaney JF, Vita JA: Atherosclerosis, oxidative stress and antioxidant protection in EDRF action. Prog Cardiovasc Dis 1995;38:129-154.
38. Anderson TJ, Meredith IT, Yeung AC, Frei B, Sehvyn A, Ganz P: The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
39. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;96:1107-1113.
40. Lerman A, Holmes DR, Bell MR, Garratt KN, Nishimura RA, Burnett JC: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-2431.
41. Andersen P, Arnesen J, Hjermann I: Hyperlipoproteinemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 1981;209:199-202.
42. Hamsten A, Wiman B, de Faire U, Blomback M: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
43. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 1996;20:707-727.
44. Nitenberg A, Valersi P, Sachs R, Dali M, Aptecar E, Attali JR: Impairment of coronary vascular reserve in and ACH-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993;42:1017-1025.
45. Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, Selwyn AP, Alexander RW, Ganz P: Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992;71:776-781.
46. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
47. Nitenberg A, Antony I, Foult JM: Acetylcholine-induced coronary vasoconstriction in young, heavy smokers with normal coronary arteriographic findings. Am J Med 1993;95:71-77.
48. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield J: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-2155.
49. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE: Passive smoking and impaired endothelium-dependent arterial dilitation in healthy young adults. N Engl J Med 1996;334:150-154.
50. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:471-476.
51. Richardson M, Hadcock SJ, DeReske M, Cybulsky MI: Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 1994;14:760-769.
52. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72.
53. Palermo A, Bertalero P, Pizza N, Amelotti R, Libretti A: Decreased fibrinolytic response to adrenergic stimulation in hypertensive patients. J Hypertens 1989;7(suppl):S162-S163.
54. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes (Part 1). N Engl J Med 1992;326:242-250.
55. Ambrose JA, Winters SL, Arora RR, Haft JI, Goldstein J, Rentrop KP, Gorlin R, Fuster V: Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 1985;6:1233-1238.
56. Folland ED, Vogel RA, Hartigan P, Bates ER, Beauman GJ, Fortin T, Boucher C, Parisi AF, and the Veterans Affairs ACME Investigators: Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease. Circulation 1994;89:2005-2014.
57. Vita JA, Treasure CB, Yeung AC, Vekshtein VI, Fantasia GM, Fish RD, Ganz P, Selwyn AP: Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992;85:1390-1397.
58. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP: Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation 1989;80:458-465.
59. Bogaty P, Hackett D, Davies G, Maseri A: Vasoreactivity of the culprit lesion in unstable angina. Circulation 1994;90:5-11.
60. Okumura K, Yasue H, Matsuyama K, Ogawa H, Morikami Y, Obata K, Sakaino N: Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol 1992;19:752-758.
61. Loree HM, Kamm RD, Stringfellow RG, Lee RT: Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992;71:850-858.
62. Vita JA, Treasure CB, Ganz P, Cox DA, Fish RD, Selwyn AP: Control of shear stress in the epicardial coronary arteries of humans: impairment by atherosclerosis. J Am Coll Cardiol 1989;14:1193-1199.
63. Golino P, Piscione F, Willerson JT, Capelli-Bigazzi M, Focaccio A, Villari B, Indolfi C, Russolillo E, Condorelli M, Chiarello M: Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991;324:641-648.
64. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease. II. unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263.
65. Leung WH, Lau CP, Wong CK: Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341: 1496-1500.
66. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
67. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
68. Yeung A, Hodgson JM, Winniford M, Vita J, Klein L, Treasure C, Kern M, Plotkin D, Shih WC, Mitchel YB, Charbonneau F, Ganz P: Assessment of coronary vascular reactivity after cholesterol lowering (Abstr). Circulation 1996;94:1-402.
69. Vogel RA, Corretti M, Plotnick GD: Changes in Flow-Mediated Brachial Artery Vasoactivity with lowering of Desirable Cholesterol Levels in Healthy, Middle-aged Men. Am J Cardiol 1995;77:37-40.
70. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-Coenzyme a reductase inhibitor, improves endothelium function within 1 month. Circulation 1997;95:1126-1131.
71. Stadler RW, Ibrahim SF, Lees RS: Peripheral vasoreactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL precipitation (HELP). Atherosclerosis 1997;128:241-249.
72. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Iamaizumi T: Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997;95:76-82.
73. Wada H, Mon Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, Ohiwa M, Tamaki S, Tanigawa M, Kageyama S et al: Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993;44:112-116.
74. Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K, Gotto AM, Ballantyne CM: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
75. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-1538.
76. Andrews TC, Raby K, Barry J, Naimi CL, Alfred E, Ganz P, Selwyn AP: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-328.
77. Waters D, Craven TE, Lesperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87: 1067-1075.
78. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA: Estrogen improves endothelium-dependent, flow mediated vasodilation in post menopausal women. Ann Intern Med 1994;121:936-941.
79. Grodstein F, Stampfer M: The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
80. Paffenbarger RSJ, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB: The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993;328:538-545.
81. Blair SN, Kohl HW, Barlow CE, Paffenbarger RSJ, Gibbons LW, Macera CA: Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. JAMA 1995;273:1093-1098.
82. Niebauer J, Cooke JP: Cardiovascular Effects of Exercise: Role of Endothelial Shear Stress. J Am Coll Cardiol 1996;28:1652-1660.
83. Wang J, Wolin MS, Hintze TH: Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs. Circ Res 1993;73:829-838.
84. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH: Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353.
85. Hornig B, Maier V, Drexler H: Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996;93:210-214.
86. Clarkson P, Montgomery H, Donald A, Powe A, Bull T, Dollery C, Jubb M, World M: Exercise training enhances endothelial function in young men (Abstr). J Am Coll Cardiol 1996: 288A.
87. Stratton JR, Chandler WL, Schwartz RS, Cerqueira MD, Levy WC, Kahn SE, Larson VG, Cain KC, Beard JC, Abrass IB: Effects of physical conditioning on fibrinolytic variables and fibrinogen in young and old healthy adults. Circulation 1991;83:1692-1697.
88. Haskell WL, Sims C, Myll J, Bortz WM, St. Goar FG, Alderman EL: Coronary artery size and dilating capacity in ultradistance runners. Circulation 1993;87:1076-1082.
89. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ: Angiotensin-Converting enzyme inhibition with Quinapril improves endo thelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-265.
90. Schiffrin EL, Deng LY: Comparison of effects of angiotensin I-converting enzyme inhibition and beta blockade for 2 years on function of small arteries from hypertensive patients. Hyperten sion 1995;25:699-703.
91. Panza JA, Quyyumi AA, Callahan TS, Epstein SE: Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993;21:1145-1151.
92. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-786.
93. Clarkson P, Adams MR, Powe AJ: Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1994;67:1989-1994.